中文 | English



李诗良,博士

副教授,硕士生导师

邮箱:shiliangli@ecust.edu.cn

地址:上海市徐汇区梅陇路130号华东理工大学实验18516

  

教育背景

(1)2011-09 至 2016-06,华东理工大学,药学, 博士(导师:李洪林 教授)
(2)2007-09 至 2011-06,华东理工大学,制药工程,学士(导师:李洪林 教授)


科研与学术工作经历

(1)2019-08 至今,华东理工大学,药学院,副教授

(2)2018-11 至 2019-07,华东理工大学,药学院,特聘副研究员

(3)2016-07 至 2018-10,华东理工大学,博士后(导师:徐玉芳 教授


研究方向

(1)基于结合热/动力学的药物设计

(2)人工智能药物设计方法开发与应用


个人简介

 主要聚焦导致药物临床失败的关键问题如药效不足和安全性差等,通过发展药物设计新方法和新技术,针对危及人民生命健康的重大疾病,开展应用研究,发现多类新型强效的候选药物。取得的成绩:1)自主发展新的药物设计方法及程序5套,获软件版权2项;2)通过开发及使用多策略药物设计方法,针对重大疾病如癌症、糖尿病及自身免疫性疾病相关的重要靶标进行系统性药物设计研究,发现多类骨架新颖的活性化合物和先导结构,参与设计的分子中现已有31类和12类候选新药完成技术成果转化,其中2个进入临床研究;3)在Protein & Cell, APSB, J. Med. Chem.等专业期刊上发表SCI论文43篇,H指数为12,总他引600多次;包括第一/通讯论文22篇,其中一区论文6篇,二区论文6篇,IF>510篇;4)申请发明专利14项,转国际PCT专利5项;中国授权专利4项,其中1件专利在国外6个国家和地区授权;5)主持国家、省部级科研项目5项,包括国自然面上和青年项目、上海市“扬帆”计划、中国博士后面上一等资助等。


承担科研项目

(1)国家自然科学基金委员会,专项项目,82150208,2022-01-01至2024-12-31,280万元,在研,参与

(2)国家自然科学基金委员会,面上项目,82173690,2022-01-01至2025-12-31,55万元,在研,主持

(3)国家自然科学基金委员会,青年科学基金项目,81803437,2019-01-01至2021-12-31,21万元,在研,主持

(4)临港实验室,“求索杰出青年计划”开放课题,LG-QS-202206-02,2022-01 至 2024-12,300万元,在研,主持

(5)上海市科委,青年科技英才扬帆计划,18YF1405100,2018-05 至 2021-04,20万元,结题,主持

(6)科技部,国家“重大新药创制”科技重大专项子课题,2018ZX09711002-001-009,2018-01  至 2020-12,241.07万元,结题,参与

(7)中国博士后科学基金会,面上资助,2016M600290,2016-11 至 2018-07,8万元,结题,主持

 

代表性论文(第一作者或通讯作者)

(1) Xiong, Rui#; Zhang, Leike#; Li, Shiliang#;  Sun, Yuan; Ding, Minyi; Wang, Yong; Zhao, Yongliang; Wu, Yan; Shang,  Weijuan; Jiang, Xiaming; Shan, Jiwei; Shen, Zihao; Tong, Yi; Xu, Liuxin;  Chen, Yu; Liu, Yingle; Zou, Gang; Lavillete, Dimitri; Zhao, Zhenjiang;  Wang, Rui; Zhu, Lili; Xiao, Gengfu; Lan, Ke; Li, Honglin*; Xu, Ke*; Novel  and potent inhibitors targeting DHODH are broad-spectrum antivirals  against RNA viruses including newly-emerged coronavirus SARS-CoV-2, Protein & Cell, 2020, 11(10): 723-739.(封面文章)

(2) Zeng, Fanxun#; Li, Shiliang#;  Yang, Guantian#; Luo, Yating#; Qi, Tiantian; Liang, Yingfan; Yang, Tingyuan; Zhang, Letian; Wang, Rui*; Zhu, Lili*; Li, Honglin*; Xu, Xiaoyong*  ; Design, synthesis, molecular modeling, and biological  evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis., Acta Pharmaceutica Sinica B, 2020, 11(3): 795-809.(封面文章)

(3) Li, Shiliang#;  Qin, Chun#; Cui, Shichao#; Xu, Hongling; Wu, Fangshu; Wang, Jiawei; Su,  Mingbo; Fang, Xiaoyu; Li, Dan; Jiao, Qian; Zhang, Ming; Xia, Chunmei;  Zhu, Lili; Wang, Rui; Li, Jia; Jiang, Hualiang; Zhao, Zhenjiang*; Li,  Jingya*; Li, Honglin*; Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes, Journal of Medicinal Chemistry, 2019, 62(5): 2348-2361.(封面文章)

(4) Yuan,  Yuan#; Xu, Junpeng#; Jiang, Lei#; Yu, Kangjie; Ge#, Yuanyuan; Li, Mingyang;  He, Huan; Niu, Qiqi; Shi, Xiayu; Fan, Linni; Chen, Zhuo; Zhao,  Zhenjiang; Li, Shiliang*; Xu, Yufang*; Wang, Zhe*; Li, Honglin*; Discovery,  Optimization, and Structure-Activity Relationship Study of Novel and  Potent RSK4 Inhibitors as Promising Agents for the Treatment of  Esophageal Squamous Cell Carcinoma, Journal of Medicinal Chemistry, 2021, 64(18): 13572-13587.

(5) Li Shiliang#;  Xu Hongling#; Cui Shichao#; Wu Fangshu; Zhang Youli; Su Mingbo; Gong  Yinghui; Qiu Shaobing; Jiao Qian; Qin Chun; Shan Jiwei; Zhang Ming; Wang  Jiawei; Yin Qiao; Xu Minghao; Liu Xiaofeng; Wang Rui; Zhu Lili; Li Jia;  Xu Yufang; Jiang Hualiang; Zhao Zhenjiang*; Li Jingya*; Li Honglin*; Discovery and Rational Design of Natural-Product-Derived  2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and  Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of  Type 2 Diabetes, Journal of Medicinal Chemistry, 2016, 59(14): 6772-6790.

(6) Li Shiliang#; Zhou Yi#; Lu Weiqiang#; Zhong Ye; Song Wenlong; Liu Kangdong; Huang Jin*; Zhao Zhenjiang; Xu Yufang; Liu Xiaofeng*; Li Honglin ; Identification  of Inhibitors against p90 Ribosomal S6 Kinase 2 (RSK2) through  Structure-Based Virtual Screening with the Inhibitor-Constrained Refined  Homology Model, Journal of Chemical Information and Modeling, 2011, 51(11): 2939-2947.

(7) Yang Gui Xiang; Ge Song Lan; Wu Yan; Huang Jin; Li Shiliang*; Wang Rui*; Ma Lei *; Design,  synthesis and biological evaluation of 3-piperazinecarboxylate  sarsasapogenin derivatives as potential multifunctional anti-Alzheimer  agents, European Journal of Medicinal Chemistry, 2018, 156: 206-215.

(8) Li, Shiliang; Cai, Chaoqian; Gong, Jiayu; Liu, Xiaofeng; Li, Honglin*; A fast protein binding site comparison algorithm for proteome-wide protein function prediction and drug repurposing, Proteins: Structure, Function, and Genetics, 2021, 89(11): 1541-1556.(封面文章)

(9) Wang, Disha; Liu, Wenjun; Shen, Zihao; Jiang, Lei; Wang, Jie; Li, Shiliang*; Li, Honglin*; Deep Learning Based Drug Metabolites Prediction, Frontiers in Pharmacology, 2020, 10: 0-1586.

(10) Luo, Na; Fang, Xiaoyu; Su, Mingbo; Zhang, Xinwen; Li, Dan; Li, Honglin; Li, Shiliang*; Zhao, Zhenjiang*; Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors, Chinese Journal of Chemistry, 2021, 39(1): 115-120.

(11) He Gaoqi; Gong Bojie; Li Jianqiang; Song Yiping; Li Shiliang*; Lu Xingjian *; An Improved Receptor-Based Pharmacophore Generation Algorithm Guided by Atomic Chemical Characteristics and Hybridization Types, Frontiers in Pharmacology, 2018, 9: 0-1463.

(12) Meng Jiajia#; Li Shiliang#; Liu Xiaofeng; Zheng Mingyue; Li Honglin*; RD-Metabolizer:  an integrated and reaction types extensive approach to predict  metabolic sites and metabolites of drug-like molecules, Chemistry Central Journal, 2017, 11: 0-65.

(13) Li Shiliang#;  Luan Guoqin#; Ren Xiaoli#; Song Wenlin; Xu Liuxin; Xu Minghao; Zhu  Junsheng; Dong Dong; Diao Yanyan; Liu Xiaofeng; Zhu Lili; Wang Rui; Zhao  Zhenjiang*; Xu Yufang*; Li Honglin*; Rational Design of  Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent  Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo  Anti-arthritic Activity, Scientific Reports, 2015, 5: 0-14836.

(14) Li, Qiannan#; Zhang, Tao#; Li, Shiliang#;  Tong, Linjiang; Li, Junyu; Su, Zhicheng; Feng, Fang; Sun, Deheng; Tong,  Yi; Wang, Xia; Zhao, Zhenjiang; Zhu, Lili; Ding, Jian; Li, Honglin*;  Xie, Hua*; Xu, Yufang *; Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFR(L858R/T790M/C797S), ACS Medicinal Chemistry Letters, 2019, 10(6): 869-873.

(15) Qiu Che#; Yuan Zhen#; He Zhiyan; Chen Huiwen; Liao Yue; Li Shiliang*; Zhou Wei*; Song Zhongchen*; Lipopolysaccharide  Preparation Derived From Porphyromonas gingivalis Induces a Weaker  Immuno-Inflammatory Response in BV-2 Microglial Cells Than Escherichia  coli by Differentially Activating TLR2/4-Mediated NF-κB/STAT3 Signaling  Pathways, Frontiers in Cellular and Infection Microbiology, 2021, 11.